We have found that Akt signaling contributes to some of the more notable abnormalities in tumor vascular itroma. Those vascular abnormalities include the propensity for excessive vascular permeability leading to tissue edema and sluggish blood flow, extravasation of fibrin and other matrix proteins that alter the extracellular microenvironment, and the trafficking of inflammatory cells in and out of the tumor-associated vasculature. In addition, we also showed that rapamycin is an effective inhibitor of Akt signaling in the tumor stroma. This grant application has two major goals: (1) to study rapamycin's effects on the tumor stroma and to determine the i.npact of the anti-stromal effects of rapamycin on its anti-tumor efficacy. Both vascular and nonvascular stroma will be studied. (2) to investigate the contribution to angiogenesis by key molecules in the Akt-mTOR pathway that may be critical for the observation effects of rapamycin.
Aim 1 is focused on dentification of the vessel targets of rapamycin.
Aim 2 is designed to explore the effects of rapamycin on the non-vascular tumor stroma Aim 3 investigates rapamycin inhibition of tumor cell trafficking across the endothelium in metastasis. In addition to examing rapamycin's effects, all three aims contain some investigations of individual molecules in the Akt-mTor pathway. A particular focus is proposed to examine Akt isoforms and the TORCH feedback to Akt in the regulation of angiogenesis and endothelial trafficking in order to better understand the key regulatory molecules that are affected by rapamycin to mediate the observed anti-stromal phenotypes.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-GRB-S)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Beth Israel Deaconess Medical Center
United States
Zip Code
Sitohy, Basel; Chang, Sunghee; Sciuto, Tracey E et al. (2017) Early Actions of Anti-Vascular Endothelial Growth Factor/Vascular Endothelial Growth Factor Receptor Drugs on Angiogenic Blood Vessels. Am J Pathol 187:2337-2347
Gross, Kayla; Wronski, Ania; Skibinski, Adam et al. (2016) Cell Fate Decisions During Breast Cancer Development. J Dev Biol 4:4
Sedic, Maja; Kuperwasser, Charlotte (2016) BRCA1-hapoinsufficiency: Unraveling the molecular and cellular basis for tissue-specific cancer. Cell Cycle 15:621-7
Sedic, Maja; Skibinski, Adam; Brown, Nelson et al. (2015) Haploinsufficiency for BRCA1 leads to cell-type-specific genomic instability and premature senescence. Nat Commun 6:7505
Mazumdar, Sohini; Arendt, Lisa M; Phillips, Sarah et al. (2015) CoREST1 promotes tumor formation and tumor stroma interactions in a mouse model of breast cancer. PLoS One 10:e0121281
Dvorak, Harold F (2015) Tumor Stroma, Tumor Blood Vessels, and Antiangiogenesis Therapy. Cancer J 21:237-43
Sciuto, Tracey E; Merley, Anne; Lin, Chi-Iou et al. (2015) Intracellular distribution of TM4SF1 and internalization of TM4SF1-antibody complex in vascular endothelial cells. Biochem Biophys Res Commun 465:338-43
Kaunisto, Aura; Henry, Whitney S; Montaser-Kouhsari, Laleh et al. (2015) NFAT1 promotes intratumoral neutrophil infiltration by regulating IL8 expression in breast cancer. Mol Oncol 9:1140-54
Dvorak, Harold F (2015) Tumors: wounds that do not heal-redux. Cancer Immunol Res 3:1-11
Skibinski, Adam; Breindel, Jerrica L; Prat, Aleix et al. (2014) The Hippo transducer TAZ interacts with the SWI/SNF complex to regulate breast epithelial lineage commitment. Cell Rep 6:1059-1072

Showing the most recent 10 out of 117 publications